JPMorgan Chase & Co. set a GBX 7,900 ($103.23) price objective on AstraZeneca (LON:AZN) in a research report sent to investors on Friday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other analysts have also recently issued reports on the stock. HSBC set a GBX 6,235 ($81.47) price target on shares of AstraZeneca and gave the company a sell rating in a report on Thursday, October 17th. Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a report on Friday. Deutsche Bank reaffirmed a buy rating and issued a GBX 8,300 ($108.45) price target on shares of AstraZeneca in a report on Thursday. Citigroup reaffirmed a buy rating on shares of AstraZeneca in a report on Thursday. Finally, Goldman Sachs Group set a GBX 5,500 ($71.87) price target on shares of AstraZeneca and gave the company a sell rating in a report on Wednesday, October 30th. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a buy rating to the company’s stock. AstraZeneca currently has a consensus rating of Hold and a consensus price target of GBX 7,465.67 ($97.55).
Shares of LON AZN traded down GBX 10 ($0.13) during trading on Friday, reaching GBX 7,277 ($95.09). 1,564,493 shares of the stock were exchanged, compared to its average volume of 2,310,000. The business’s 50-day moving average price is GBX 7,153.54 and its 200 day moving average price is GBX 6,640.56. AstraZeneca has a twelve month low of GBX 5,312 ($69.41) and a twelve month high of GBX 8,227.88 ($107.51). The company has a quick ratio of 0.70, a current ratio of 0.92 and a debt-to-equity ratio of 148.59. The company has a market capitalization of $95.47 billion and a price-to-earnings ratio of 45.65.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: What is a CD ladder?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.